Biomarker and Genetic Predictors of Erenumab Treatment Response

Inclusion Criteria: * Subject has provided informed consent prior to initiation of any study-specific activities/procedures * Age greater than or equal to 18 years upon entry into screening * History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self report * Greater than or equal to 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening After baseline period * Must have demonstrated greater than or equal to 75% compliance in eDiary usage during baseline period Exclusion Criteria: Subjects are excluded from the study if any of the following criteria apply: Disease Related * Greater than 50 years of age at migraine onset * History of cluster headache or hemiplegic migraine headache * Inability to differentiate between migraine from other headaches. Other Medical Conditions * The subject is at risk of self-harm or harm to others as evidenced by past suicidal behaviour * History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. Prior/Co…